Clinical trials
Chronic Kidney Disease Stage 3 clinical trials
Below are recruiting chronic kidney disease stage 3 clinical trials, each written for real people, not researchers. We’re tracking 196 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06173947Recruiting
SSM Score for Liver Injury in Chronic Liver Disease
This study looks at how well a simple score (called SSM) can predict recovery in people with chronic liver disease who suddenly get a liver injury with jaundice. It may help your doctors understand how serious your condition is.
Guangzhou, GuangdongAges 18–80 - NCT06708338Recruiting
Bevel direction during dialysis fistula puncture
This study looks at which way the needle bevel should face when starting dialysis through a new fistula. It might help reduce pain or damage to the fistula.
Le Puy-en-VelayAges 18–85 - NCT06408077Recruiting
How sodium levels are managed in kidney failure
This study looks at how the body handles salt (sodium) in people with end-stage kidney disease who are on dialysis. If you join, researchers will test how your body responds to changes in fluids and salt levels.
CologneAges 18 years+ - NCT06341452Recruiting
Comparing custom salt levels vs. standard care in dialysis
This trial tests if adjusting the salt (sodium) in your dialysis fluid can improve your health. It is for people on dialysis who have trouble with too much fluid gain or high blood pressure between sessions.
Mariánské LázněAges 18 years+ - NCT05786443RecruitingPhase 2
Empagliflozin test in adults on regular dialysis
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Boston, MassachusettsAges 18 years+ - NCT06772454Recruiting
Testing a new drug combo for advanced lung cancer with COPD
This trial tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and inhaled steroids helps people with advanced lung cancer who also have COPD. The goal is to see if this combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07707271Recruiting
Continuous vs. interval exercise for COPD
This trial compares two types of exercise training—steady moderate exercise versus short bursts of higher intensity—to see which is more helpful for people with COPD. It aims to find a better way to improve your breathing and fitness.
Thessaloniki, ExohiAges Any age - NCT06976762Enrolling by invitation
Light-based muscle oxygen measurements in COPD with kidney disease
This study uses a special light-based device (near-infrared spectroscopy) to measure muscle oxygen levels in people who have both COPD and chronic kidney disease. Researchers want to see if these measurements can help predict how the disease progresses, which could lead to better monitoring and treatment.
Tokat ProvinceAges 18–80 - NCT05743582Recruiting
Studying natural immunity in COPD and in healthy adults
This study looks at how the body’s “innate” (first-line) immune system works in people with COPD compared with healthy volunteers. It may help researchers understand COPD inflammation and how immune responses could be targeted in the future.
EdinburghAges 18–77 - NCT06082063RecruitingPhase 3
Reducing heart disease risk in type 1 diabetes
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
CopenhagenAges 40–90 - NCT07509034RecruitingPhase 1
Targeted immune cells for recurrent small cell lung cancer
This trial tests a special immune cell therapy (CAR T cells) that targets a protein called B7-H3 on your cancer cells. It is for people with small cell lung cancer or similar neuroendocrine cancers that have returned or not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT06525909Recruiting
Immune status in chronic hepatitis B
This study looks at how the immune system changes over time in people with chronic hepatitis B. It will help doctors better understand the stages of the disease to guide treatment decisions.
Wuhan, HubeiAges 18–50 - NCT07624305RecruitingPhase 3
Balcinrenone and Dapagliflozin for Moderate-to-Severe Kidney Disease
This study tests a combination of two medications (balcinrenone and dapagliflozin) to help protect your kidneys if you have moderate-to-severe chronic kidney disease. The trial evaluates whether this combination slows kidney damage and improves kidney health.
Huntsville, AlabamaAges 18–99 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT06661720RecruitingPhase 3
Tivozanib and pembrolizumab after kidney cancer surgery
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
Phoenix, ArizonaAges 18 years+ - NCT07240896RecruitingEarly Phase 1
Testing a new mRNA therapy for Wilson disease
This trial tests an experimental mRNA treatment (DSL101) for adults with Wilson disease. It's for people whose condition is stable on current therapy and who have certain genetic markers. The goal is to see if the new treatment can help the body process copper better and reduce the need for standard medicines.
Hefei, AnhuiAges 18 years+ - NCT05508009RecruitingPhase 1/Phase 2
Kidney transplant with donor-matched stem cell treatment
This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.
Palo Alto, CaliforniaAges 1–30 - NCT06919003RecruitingPhase 2
Improving kidney transplant with a single injection of a protective protein
This trial tests whether a single injection of C1 esterase inhibitor into a donated kidney during preservation can improve transplant outcomes. It is for adults on dialysis waiting for a deceased-donor kidney who meet specific blood and tissue matching requirements.
Los Angeles, CaliforniaAges 18–75 - NCT04823923Recruiting
How kidney failure affects drug levels in metastatic kidney cancer
This study looks at how chronic kidney failure changes the amount of certain cancer medicines in the blood. It involves people with metastatic clear cell kidney cancer who take pazopanib or cabozantinib, and compares drug levels in different kidney function groups.
MarseilleAges 18 years+ - NCT07383441RecruitingPhase 3
Adding Biotherapy or Placebo to Standard Kidney Cancer Treatment
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
Fayetteville, ArkansasAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+
Hear when a new Chronic Kidney Disease Stage 3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic kidney disease stage 3?
- Yes. Clin2 currently lists 196 recruiting chronic kidney disease stage 3 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic kidney disease stage 3 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic kidney disease stage 3 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.